SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007861
Filing Date
2024-05-13
Accepted
2024-05-13 07:10:42
Documents
78
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20240331x10q.htm   iXBRL 10-Q 1585548
2 EX-31.1 apge-20240331xex31d1.htm EX-31.1 13522
3 EX-31.2 apge-20240331xex31d2.htm EX-31.2 13706
4 EX-32.1 apge-20240331xex32d1.htm EX-32.1 12164
  Complete submission text file 0001558370-24-007861.txt   7023950

Data Files

Seq Description Document Type Size
5 EX-101.SCH apge-20240331.xsd EX-101.SCH 50881
6 EX-101.CAL apge-20240331_cal.xml EX-101.CAL 35266
7 EX-101.DEF apge-20240331_def.xml EX-101.DEF 233880
8 EX-101.LAB apge-20240331_lab.xml EX-101.LAB 435797
9 EX-101.PRE apge-20240331_pre.xml EX-101.PRE 386203
82 EXTRACTED XBRL INSTANCE DOCUMENT apge-20240331x10q_htm.xml XML 1039397
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

IRS No.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 24936852
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)